Posts by: Joana Carvalho

News

Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based ... Read more

October 26, 2018

Orgenesis, Hemogenyx Collaborating on Cell Replacement Technology for Blood Cancers

News

Orgenesis has partnered with Hemogenyx Pharmaceuticals to drive the development and commercialization of Hemogenyx’s human postnatal hemogenic endothelial cell (Hu-PHEC) technology for the treatment of blood cancers. Hu-PHEC is a cell replacement technology ... Read more

October 24, 2018

Leukemia and Lymphoma Society Grants $5M for Development of Blood Cancer Immunotherapies

News

A team of Texas researchers received a grant of $5 million from the Leukemia and Lymphoma Society to develop targeted immunotherapies for blood cancers. The Specialized Center of Research (SCOR) grant will ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness ... Read more

September 10, 2018

Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows

News

TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. ... Read more

August 14, 2018

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

News

ADC Therapeutics has dosed the first participant in its Phase 2 trial assessing ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is expected to support ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, ... Read more

July 19, 2018

Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients

News

European patients with non-Hodgkin’s lymphoma (NHL) are more likely to receive rituximab biosimilars if they are fitter, have indolent disease, or follicular lymphoma, according to a new study. The study, “Treatment approach ... Read more

June 25, 2018December 6, 2018

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

News

Kymriah (tisagenlecleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Novartis, is able to ellicit prolonged complete responses with minor side effects in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), ... Read more

Posts by: Joana Carvalho

Joana Carvalho

Exposure to Glyphosate in Herbicides Increases Risk of Non-Hodgkin’s Lymphoma, Study Says

Orgenesis, Hemogenyx Collaborating on Cell Replacement Technology for Blood Cancers

Leukemia and Lymphoma Society Grants $5M for Development of Blood Cancer Immunotherapies

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

Pin It on Pinterest